Table 3.

Univariate and mutivariate analysis for overall survival (OS)

Variables	Univariate analysis			Multivariate analysis
	HR	95% CI	p	HR	95% CI	p
Age (> 79 vs. ≤ 79)	3.65	2.03–6.55	< 0.001	1.09	1.005–1.18	0.037
Gender (male vs. female)	0.79	0.44–1.42	0.44
PS (> 1 vs. ≤ 1)	2.63	1.37–5.014	0.002	2.36	1.01–5.53	0.045
Immunosupression (yes vs. no)	1.25	0.68–2.28	0.48
Location (cervico-encephalic vs. others)	1.54	0.85–2.76	0.15
Presentation (nodular vs. others)	1.16	0.65–2.09	0.61
Stage (> I vs. ≤ I)	1.34	0.74–2.44	0.35
Angiolymphatic vascular emboli (yes vs. no)	2.25	1.05–4.79	0.007	4.84	1.58–14.80	0.006
Perinervous sheathings (yes vs. no)	1.53	0.73–3.21	0.19
Lymph node involvement (yes vs. no)	1.08	0.57–2.08	0.80
SBLN (yes vs. no)	0.38	0.17–0.86	0.09
Lymph node dissection (yes vs. no)	0.62	0.31–1.25	0.24
Radiotherapy (yes vs. no)	0.33	0.15–0.73	< 0.001	0.45	0.37–0.92	0.041
Dose (> 50 Gy vs. ≤ 50 Gy)	0.28	0.08–0.89	< 0.001	0.95	0.51–1.63	0.25
Lymph node radiotherapy (yes vs. no)	0.47	0.21–1.12	0.063
Type of TILs (B vs. NB)	0.39	0.18–0.83	0.043
CD3 (≥ 1% vs < 1%)	0.35	0.12–0.53	0.026
CD8 (≥ 1% vs < 1%)	0.47	0.23–0.97	0.045
CD68 (≥ 1% vs. < 1%)	0.86	0.32–2.35	0.79
PD-L1 IC (≥ 1% vs. < 1%)	0.34	0.09–0.69	0.010	0.43	0.20–0.79	0.006
PD-L1 TC (≥ 1% vs. < 1%)	0.39	0.18–0.83	0.009	0.82	0.31–2.15	0.69
PD-L1 Tt (≥ 1% vs < 1%)	0.76	0.34–1.69	0.47
PD1 (≥ 1% vs. < 1%)	1.06	0.51–2.19	0.87
FoxP3 (≥ 1% vs. < 1%)	0.94	0.43–2.09	0.89
MCPyV (positive vs. negative)	0.34	0.16–0.71	0.004	0.69	0.26–1.80	0.45

Significant results are given in bold

PS performance status, TB  tumor bed, SBLN sentinel lymph node biopsy, TILs tumor-infiltrating lymphocytes, CD3-8–68  cluster of differentiation 3–8-68, PD-L1 programmed cell death-ligand 1, IC immune cells, TC tumor cells, TT total, PD-1 programmed cellle death 1, MCPy Merkel cell polyomavirus, FOXP3 forkhead box P3